Alzheimer's disease drug not recommended

The first drug to be licensed in Britain for the symptomatic treatment of mild to moderately severe Alzheimer's disease has failed to be recommended by the Drug and Therapeutics Bulletin. The report produced by the Consumers' Association concluded: “On the published evidence available we cannot recommend the use of donepezil.”.

Donepezil (Aricept) is an acetylcholinesterase inhibitor that increases the concentration of acetylcholine at …